UPDATE: Goldman Sachs Initiates Coverage on Micromet

Goldman Sachs has published a research report on Micromet Inc initiating coverage of the company. In the report, Goldman Sachs wrote, "We are at Neutral as we believe the current valuation reflects the prospects of Bmab for ALL as well as the company's proprietary nextgeneration antibody platform. We also see a lack of near term catalysts as the company is in the midst of executing on the pivotal trial program for Bmab (with data expected in 2013/2014)." Goldman Sachs rated Micromet Inc a Neutral with a price target of $5.00. Micromet closed Tuesday at $4.98.